Financial neutrality and the prohibition on valuable consideration

Financial neutrality is the principle that a person who donates an organ should neither profit from nor be financially burdened by the donation: donors and their families "neither lose nor gain financially as a result of donation."[1] In the United States this principle is anchored in a statutory prohibition on the sale of human organs. The National Organ Transplant Act (NOTA) of 1984 makes it a federal crime to transfer a human organ "for valuable consideration" for use in human transplantation, while carving out reimbursement of legitimate, non-profit-making donation costs.[2] The result is a regime in which organs are treated as a donated gift rather than a commodity, but in which the out-of-pocket and indirect costs borne by living donors may be reimbursed, most prominently through the federally funded National Living Donor Assistance Center (NLDAC).[3]

The NOTA prohibition

The operative federal provision is 42 U.S.C. § 274e, enacted as part of NOTA. It states that "it shall be unlawful for any person to knowingly acquire, receive, or otherwise transfer any human organ for valuable consideration for use in human transplantation if the transfer affects interstate commerce."[2] A person who violates the prohibition "shall be fined not more than $50,000 or imprisoned not more than five years, or both."[2]

The statute defines "human organ" to include the kidney, liver, heart, lung, pancreas, bone marrow, cornea, eye, bone, and skin, or any subpart thereof, and any other organ specified by the Secretary of Health and Human Services by regulation.[2]

The prohibition is not absolute. The statutory definition of "valuable consideration" expressly excludes:[2]

• "the reasonable payments associated with the removal, transportation, implantation, processing, preservation, quality control, and storage of a human organ", the operating costs of the transplant system itself; and
• "the expenses of travel, housing, and lost wages incurred by the donor of a human organ in connection with the donation of the organ."

These exclusions are what make the system workable: surgeons, organ procurement organizations, transplant hospitals, and tissue processors may all be paid for services rendered without those payments being treated as the purchase of an organ. What is prohibited is payment to a donor or next of kin in exchange for the organ itself.

The Charlie W. Norwood Living Organ Donation Act (2007)

In December 2007 Congress amended § 274e through the Charlie W. Norwood Living Organ Donation Act (enacted within Public Law 110-144).[4] The amendment clarified that "human organ paired donation", in which two or more incompatible donor-recipient pairs exchange organs so that each recipient receives a compatible organ, does not constitute a transfer for valuable consideration and therefore does not violate NOTA.[4][5] Before the amendment, some legal commentators had worried that kidney paired donation might fall within the literal text of the sale ban, since each donor's gift is contingent on another donor's gift; the Act removed that uncertainty and enabled the growth of formal kidney paired donation programs.[5] A 2007 U.S. Department of Justice Office of Legal Counsel opinion had separately analyzed the legality of paired-donation arrangements under § 274e.[5]

The financial-neutrality principle

The exclusions for travel, housing, and lost wages reflect a policy goal broader than merely permitting reimbursement: that of financial neutrality. The aim is to ensure that a willing living donor is not deterred by, or left worse off because of, the substantial indirect costs of donation, travel to a distant transplant center, lodging during evaluation and recovery, missed income during surgery and convalescence, and dependent-care costs, while stopping short of any payment that would amount to buying the organ.[1][3] Financial neutrality is widely endorsed as the ethical middle ground between an outright market in organs (prohibited) and a system that silently imposes the financial costs of an altruistic act on the donor.

The Declaration of Istanbul adopts the same definition explicitly: "Financial neutrality in organ donation means that donors and their families neither lose nor gain financially as a result of donation," and its Principle 4 states that "organ donation should be a financially neutral act."[1]

The National Living Donor Assistance Center (NLDAC)

The principal U.S. mechanism for operationalizing financial neutrality for living donors is the National Living Donor Assistance Center (NLDAC), a program funded by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services and operating since 2007.[3][6] NLDAC reimburses eligible living organ donors for costs that the statute permits, travel, lodging, meals, lost wages, and dependent-care expenses incurred during donor evaluation, the donation surgery, and follow-up.[3][6]

Key features of the program (as of 2024-2026):[3][6]

• Means-tested eligibility. Historically, eligibility was benchmarked to the recipient's household income (generally at or below 300% of the federal poverty guidelines), on the rationale that the recipient is the primary beneficiary of the transplant; recipients above the threshold could apply for a financial-hardship waiver. Applicants must be U.S. citizens or lawfully present and reside in the United States or its territories.
• Covered donors. Living kidney, liver, and (more recently) uterus donors are eligible.
• Mechanics. Approved donors receive a restricted-use payment card for travel, lodging, and meals (including for an accompanying support person); lost wages and dependent-care costs are reimbursed by direct deposit or check, subject to a per-donor cap.[6]

By design NLDAC reimburses documented costs rather than paying donors a benefit; it therefore implements financial neutrality without crossing into prohibited "valuable consideration." The program reports having helped facilitate thousands of living-donor transplants by reimbursing tens of millions of dollars in donor costs.[3]

Reimbursable versus prohibited

The line drawn by § 274e and refined in practice can be summarized as follows:[2][3]

• Permitted: reimbursement of a living donor's travel, lodging, meals, lost wages, and dependent-care costs; payment to surgeons, hospitals, OPOs, and tissue processors for services and processing; paired-donation exchanges.
• Prohibited: any payment, of money or other value, to a donor or next of kin in exchange for the organ; brokered sale of organs; inducements that function as a price for the organ.

Debate over incentives and regulated markets

Whether the United States should move beyond cost reimbursement toward affirmative financial incentives for donation is the subject of an active and unresolved policy debate, which the encyclopedia presents without endorsing any position.

Proponents of expanded incentives argue that the organ shortage and the resulting deaths on the waiting list justify measures such as refundable tax credits, contributions to retirement accounts, guaranteed health or life insurance, or other government-provided benefits for donors; some have proposed legislation (for example, versions of an "Organ Donor Clarification Act") to authorize pilot programs testing non-cash incentives that would not constitute prohibited "valuable consideration."[7] Critics counter that any incentive risks commodifying the body, coercing the poor, undermining altruistic donation, and eroding the very financial-neutrality norm the system rests on.[7]

Iran is frequently cited in this debate as the one country operating a government-regulated, compensated living-kidney-donation system; commentators dispute whether its model has genuinely eliminated its waiting list and whether it is ethically transferable, and it is generally treated as an outlier rather than a template.[7] Internationally, the prevailing norm remains against payment (see below), and any move toward incentives in the United States would have to be reconciled with that norm and with NOTA.

International norms

The non-payment principle is embedded in the leading international instruments:

• The World Health Organization Guiding Principles on Human Cell, Tissue and Organ Transplantation, endorsed by the World Health Assembly in Resolution WHA63.22 (2010), state in Guiding Principle 5 that "cells, tissues and organs should only be donated freely, without any monetary payment or other reward of monetary value," and that purchase or sale of organs for transplantation "should be banned." The principles nonetheless permit reimbursement of "reasonable and verifiable expenses" incurred by the donor, mirroring the U.S. carve-outs.[8]
• The Declaration of Istanbul (2008, updated 2018) calls for organ donation to be a financially neutral act and for organ sales to be prohibited and criminalized, while combating organ trafficking and transplant tourism.[1]

Both instruments thus draw the same boundary as U.S. law: reimbursement of legitimate donation costs is acceptable and even encouraged, but payment for the organ itself is not.

See also

• National Organ Transplant Act (NOTA)
• Living donation
• Kidney paired donation and exchange
• Declaration of Istanbul
• Organ trafficking and transplant tourism

References

• The Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 Edition). Definitions and Principles 1-11. https://www.declarationofistanbul.org/the-declaration
• Prohibition of organ purchases, 42 U.S.C. § 274e. Legal Information Institute / U.S. Code. https://www.law.cornell.edu/uscode/text/42/274e
• National Living Donor Assistance Center (NLDAC). Program overview and FAQs. https://www.livingdonorassistance.org/Resources/FAQs
• Charlie W. Norwood Living Organ Donation Act, Pub. L. 110-144 (Dec. 21, 2007). Congress.gov / GovTrack (H.R. 710, 110th Congress). https://www.govtrack.us/congress/bills/110/hr710
• U.S. Department of Justice, Office of Legal Counsel. Legality of Alternative Organ Donation Practices Under 42 U.S.C. § 274e (2007). https://www.justice.gov/olc/opinion/legality-alternative-organ-donation-practices-under-42-usc-274e
• U.S. Department of Health and Human Services / HRSA. National Living Donor Assistance Center Program Eligibility Guidelines. https://www.hhs.gov/guidance/document/national-living-donor-assistance-center-program-eligiblity-guidelines
• National Living Donor Assistance Center, best practices and the incentives debate. Am J Transplant (2022). https://www.amjtransplant.org/article/S1600-6135(22)10039-0/fulltext
• World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation (WHA63.22, 21 May 2010), Guiding Principle 5. https://apps.who.int/gb/ebwha/pdf_files/wha63/a63_r22-en.pdf